Cadrenal Therapeutics, Inc. (CVKD) Misses Q2 EPS by 61c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections, more earnings
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts CVKD Hot Sheet
Join SI Premium – FREE
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported Q2 EPS of ($1.87), $0.61 worse than the analyst estimate of ($1.26). Revenue for the quarter came in at $0 , versus $0 reported last year.
For earnings history and earnings-related data on Cadrenal Therapeutics, Inc. (CVKD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ExxonMobil shares drop as crude oil prices tumble
- Tempus AI Inc (TEM) PT Raised to $89 at Needham
- CoreWeave shares slip despite CrowdStrike partnership
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
